Cover Image
市場調查報告書

EpiCast Report:重症肌無力的流行病學預測

EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 333941
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:重症肌無力的流行病學預測 EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024
出版日期: 2015年06月01日 內容資訊: 英文 37 Pages
簡介

全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的重症肌無力的診斷病例數,從2014年的106,845件,預計2024年增加到119,939件,以1.23%的年成長率推移。

本報告提供全球主要7個國家的重症肌無力調查分析,疾病的背景,危險因素和共生病症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 重症肌無力的流行病學預測
    • 重症肌無力的診斷病例數
    • 重症肌無力的診斷病例數:各年齡
    • 重症肌無力的診斷病例數:性別
    • 重症肌無力的標準診斷案例:各年齡
    • 重症肌無力的診斷病例數:各重症度
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER082-15

Myasthenia gravis is an autoimmune disease that affects the nerves and muscles and is characterized by muscle weakness and fatigue, especially weakness of the muscles controlling eye and eyelid movement, facial expression, chewing and talking. In some cases the muscles controlling breathing are also affected, which can lead to respiratory failure that requires intubation and mechanical ventilation, known as a myasthenic crisis. The muscle weakness seen in myasthenia gravis is most often caused by circulating antibodies that mistakenly attack healthy tissue and inhibit normal neuromuscular transmission by blocking or damaging muscle receptor cells.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of myasthenia gravis in the 7MM, from 106,845 cases in 2014 to 119,939 cases in 2024, at an Annual Growth Rate (AGR) of 1.23% in the forecast period. The highest number of diagnosed prevalent cases of myasthenia gravis fell into the =75 year age group in the 7MM. The majority of diagnosed prevalent cases of myasthenia gravis in the 7MM in 2014 were women. The US and the 5EU markets follow a similar pattern, in which Class III has the highest number of diagnosed prevalent cases. Japan, however, has more cases in Class II than any other Class.

To build the epidemiological forecast of myasthenia gravis in the 7MM, GlobalData epidemiologists reviewed the literature and obtained country-specific, population-based studies that reported myasthenia gravis prevalence as determined via medical record reviews. GlobalData epidemiologists obtained country-specific diagnosed prevalence data for the US, Italy, the UK, and Japan, thereby providing valuable analysis of epidemiological trends amongst the 7MM. This forecast also includes age- and sex-specific segmentations, thereby providing detailed information about the characteristic of the disease in each market.

Scope

  • The Myasthenia Gravis EpiCast Report provides an overview of the risk factors and global trends of myasthenia gravis in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of myasthenia gravis, segmented by sex, age, and Myasthenia Gravis Foundation of America (MGFA) classifications (Class I, Class II, Class III, Class IV, and Class V).
  • The myasthenia gravis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Myasthenia Gravis EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global myasthenia gravis market.
  • Quantify patient populations in the global myasthenia gravis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for myasthenia gravis therapeutics in each of the markets covered.
  • Identify the percentage of myasthenia gravis prevalent cases by class.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of Myasthenia Gravis (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of Myasthenia Gravis
    • 3.5.2. Age-Specific Diagnosed PrevaIent Cases of Myasthenia Gravis
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis
    • 3.5.4. Age-Standardized Diagnosed Prevalence of Myasthenia Gravis
    • 3.5.5. Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Class
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Myasthenia Gravis
  • Table 2: Global Estimates for the Diagnosed Prevalence of Myasthenia Gravis
  • Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Myasthenia Gravis
  • Table 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Myasthenia Gravis Segmented by MGFA Classifications
  • Table 5: 8MM, Sources Not Used in Epidemiological Analysis of Myasthenia Gravis
  • Table 6: 7MM, Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, All Ages, N, Select Years 2014-2024
  • Table 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, N (Row %), 2014
  • Table 8: 7MM: Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, All Ages, N (Row %), 2014

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, All Ages, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, All Ages, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Myasthenia Gravis (Cases per 100,000 Population), Both Sexes, All Ages, 2014
  • Figure 5: 7MM, Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Class, Both Sexes, All Ages, N, 2014
Back to Top